Johnson & Johnson (NYSE:JNJ) Shares Purchased by Occidental Asset Management LLC

Occidental Asset Management LLC boosted its position in Johnson & Johnson (NYSE:JNJ) by 21.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,416 shares of the company’s stock after purchasing an additional 607 shares during the period. Occidental Asset Management LLC’s holdings in Johnson & Johnson were worth $499,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Ballast Inc. raised its stake in Johnson & Johnson by 8.9% during the 2nd quarter. Ballast Inc. now owns 22,208 shares of the company’s stock valued at $3,246,000 after purchasing an additional 1,809 shares during the period. AHL Investment Management Inc. raised its stake in Johnson & Johnson by 29.8% during the 2nd quarter. AHL Investment Management Inc. now owns 22,492 shares of the company’s stock valued at $3,287,000 after purchasing an additional 5,170 shares during the period. Andrew Hill Investment Advisors Inc. acquired a new stake in Johnson & Johnson during the 2nd quarter valued at $789,000. Bridge Creek Capital Management LLC raised its stake in Johnson & Johnson by 2.8% during the 2nd quarter. Bridge Creek Capital Management LLC now owns 37,073 shares of the company’s stock valued at $5,419,000 after purchasing an additional 1,018 shares during the period. Finally, RFG Advisory LLC raised its stake in Johnson & Johnson by 7.8% during the 2nd quarter. RFG Advisory LLC now owns 18,494 shares of the company’s stock valued at $2,703,000 after purchasing an additional 1,336 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Down 0.5 %

JNJ stock opened at $159.88 on Tuesday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $175.60. The company has a 50-day moving average of $151.41 and a two-hundred day moving average of $153.07. The stock has a market capitalization of $384.78 billion, a price-to-earnings ratio of 9.97, a price-to-earnings-growth ratio of 2.63 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company had revenue of $22.45 billion during the quarter, compared to analysts’ expectations of $22.33 billion. During the same period in the prior year, the company earned $2.80 earnings per share. The business’s quarterly revenue was up 4.3% compared to the same quarter last year. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.07 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.10%. The ex-dividend date of this dividend is Tuesday, August 27th. Johnson & Johnson’s payout ratio is presently 30.92%.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on JNJ. Daiwa Capital Markets downgraded shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their target price for the company from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Bank of America dropped their price target on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. StockNews.com downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 8th. TD Securities dropped their price target on shares of Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. Finally, Sanford C. Bernstein upped their price target on shares of Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Seven investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $173.21.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.